Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types
After propensity score matching, there were a total of 18,434 patients, with 9217 patients in the obese BMI cohort and 9217 patients in the normal BMI cohort for all solid tumor malignancies. In the overall pan-cancer analysis, obese BMI was associated with significantly improved OS up to 5 years compared to the normal BMI cohort (hazard ratio [HR], 0.69 [0.66-0.72]). Subgroup analysis likewise demonstrated that obese BMI was associated with significantly improved OS up to 5 years for respiratory/intrathoracic (HR, 0.77 [0.72-0.83]), cutaneous (HR, 0.62 [0.63-0.78]), head and neck (HR, 0.67 [0.58-0.78]), gastrointestinal (HR, 0.67 [0.58-0.78]), breast (HR, 0.66 [0.55-0.79]), and genitourinary (HR, 0.57 [0.34-0.93]) malignancies (though not renal cell carcinoma specifically.) CONCLUSIONS: Obesity was associated with improved 5-year OS after treatment with ICI across various solid tumor malignancies in this electronic health record-based big data study. Further investigation is warranted to understand the mechanism of this association.
Authors
- Ramez H. W. Philips (ORCID: https://orcid.org/0000-0003-3899-6678)
- Dev Amin (ORCID: https://orcid.org/0000-0002-3007-5690)
- Daniel J. Campbell (ORCID: https://orcid.org/0000-0001-9001-5705)
- Eric V. Mastrolonardo (ORCID: https://orcid.org/0000-0002-2869-8848)
- Joseph Curry (ORCID: https://orcid.org/0000-0001-9507-4237)
- Adam Luginbuhl (ORCID: https://orcid.org/0000-0001-7682-3108)
- Scott Koeneman (ORCID: https://orcid.org/0000-0001-9928-5330)
- Nicole L. Simone (ORCID: https://orcid.org/0000-0002-7662-7470)
- Kelly Bridgham (ORCID: https://orcid.org/0000-0001-7043-0602)
- Emma De Ravin (ORCID: https://orcid.org/0000-0002-1076-1941)
- Jennifer M. Johnson (ORCID: https://orcid.org/0000-0003-4548-307X)
- David M. Cognetti (ORCID: https://orcid.org/0000-0001-7039-3055)
- Praneet C. Kaki (ORCID: https://orcid.org/0009-0005-6428-2064)
- Kathryn Nunes (ORCID: https://orcid.org/0009-0003-3657-978X)
- Pablo Llerena
Institutions
- Thomas Jefferson University (US)
- Thomas Jefferson University Hospital (US)
- Sidney Kimmel Cancer Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1002/cncr.35799
- Citations
- 12
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 12.54